Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
500

Summary

Conditions
  • Breast Neoplasms
  • Ovarian Neoplasms
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Participants will receive niraparib once a day, continuously throughout each 90-day cycle.Masking: None (Open Label)Masking Description: This will be an open-label study.Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04641247
Collaborators
Not Provided
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline